Dynavax Technologies

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical firm focused on the development and sale of vaccines. Incorporated in 1996, the company initially operated as Double Helix Corporation before adopting its current name in September of the same year. Its founders include Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz. A key scientific figure in the company's history is Robert L. Coffman, Ph.D., who served as Chief Scientific Officer from 2000. Dr. Coffman, a member of the National Academy of Sciences, made foundational discoveries in immunology, including identifying Th1 and Th2 T-cell subsets, which has been critical to understanding immune responses in infectious and allergic diseases. His work at Dynavax guided the development of the company's core technologies.

The company's business model centers on generating revenue through two primary streams: direct product sales and strategic collaborations. Its main commercial product is HEPLISAV-B, a vaccine for the prevention of Hepatitis B virus (HBV) infection in adults. Approved by the U.S. FDA on November 9, 2017, HEPLISAV-B was the first new hepatitis B vaccine in the United States in over two decades. Its primary distinguishing feature is a two-dose regimen administered over one month, which offers greater convenience and has demonstrated higher protection rates compared to the older three-dose, six-month standard. The company markets HEPLISAV-B to a range of clients, including hospitals, clinics, public health systems, and retail pharmacies, through wholesalers and specialty distributors. This product has become a significant revenue driver, capturing an estimated 45% of the U.S. adult market share by the second quarter of 2025.

The second pillar of Dynavax's business is its proprietary CpG 1018 adjuvant, a technology designed to enhance the immune response of vaccines. This adjuvant is the key component in HEPLISAV-B and is also sold to other biopharmaceutical companies for use in their vaccine development programs. This strategy created a vital revenue stream, particularly during the COVID-19 pandemic, through supply agreements with global vaccine manufacturers. Beyond COVID-19, Dynavax is actively pursuing partnerships to integrate CpG 1018 into vaccines for other infectious diseases. The development pipeline includes a shingles vaccine candidate (Z-1018) in Phase 1/2 trials, a plague vaccine in collaboration with the U.S. Department of Defense, a pandemic influenza adjuvant program, and a Lyme disease program.

Keywords: vaccine development, biopharmaceutical, HEPLISAV-B, hepatitis B vaccine, CpG 1018, vaccine adjuvant, Toll-like Receptor 9, TLR9 agonist, infectious disease prevention, immunology, shingles vaccine, plague vaccine, Robert L. Coffman, Ryan Spencer, Dennis Carson, commercial-stage biotech, vaccine commercialization, adjuvanted vaccines, public health, immunization, biodefense, vaccine pipeline, U.S. Department of Defense collaboration